$ICUI
ICU Medical Inc Stock $icui

$icui Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000088398416000084 Filed on November 09, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$95.69M	$97.11M	$90.39M
YoY Change	5.86%	12.9%	13.13%
Cost Of Revenue	$44.90M	$45.84M	$42.10M
YoY Change	6.65%	15.31%	4.73%
Gross Profit	$50.76M	$51.27M	$48.26M
YoY Change	5.19%	10.82%	21.6%
Gross Profit Margin	53.05%	52.8%	53.39%
Selling, General & Admin	$22.60M	$22.36M	$22.50M
YoY Change	0.44%	10.67%	10.84%
% of Gross Profit	44.52%	43.61%	46.63%
Research & Development	$2.700M	$3.650M	$4.100M
YoY Change	-34.15%	-13.65%	-19.61%
% of Gross Profit	5.32%	7.12%	8.5%
Depreciation & Amortization	$4.700M	$4.000M	$4.800M
YoY Change	-2.08%	-6.98%	0.0%
% of Gross Profit	9.26%	7.8%	9.95%
Operating Expenses	$25.30M	$28.82M	$26.60M
YoY Change	-4.89%	34.06%	5.14%
Operating Profit	$25.46M	$22.46M	$21.66M
YoY Change	17.56%	-9.34%	50.55%
Interest Expense		$58.00K
YoY Change
% of Operating Profit		0.26%
Other Income/Expense, Net	$300.0K	$283.0K	$100.0K
YoY Change	200.0%	23.04%	-50.0%
Pretax Income	$14.10M	$23.03M	$12.60M
YoY Change	11.9%	-7.89%	3.28%
Income Tax	$4.600M	$4.220M	$7.200M
% Of Pretax Income	32.62%	18.33%	57.14%
Net Earnings	$9.512M	$18.81M	$5.463M
YoY Change	74.12%	15.62%	-25.9%
Net Earnings / Revenue	9.94%	19.37%	6.04%
Basic Earnings Per Share	$0.58	$1.16	$0.34
Diluted Earnings Per Share	$0.54	$1.09	$0.33
COMMON SHARES
Basic Shares Outstanding	16.33M shares	16.20M shares	15.98M shares
Diluted Shares Outstanding		17.29M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$445.1M	$372.4M	$377.4M
YoY Change	17.94%	-5.51%	8.82%
Cash & Equivalents	$445.1M	$323.0M	$336.2M
Short-Term Investments	$0.00	$49.50M	$41.20M
Other Short-Term Assets	$1.740M	$10.80M	$11.70M
YoY Change	-85.13%	-48.33%	11.43%
Inventory	$49.26M	$50.95M	$43.63M
Prepaid Expenses
Receivables	$56.16M	$53.64M	$57.85M
Other Receivables	$11.20M	$15.20M	$14.40M
Total Short-Term Assets	$569.1M	$503.0M	$505.0M
YoY Change	12.69%	-2.07%	16.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.70M	$80.59M	$74.32M
YoY Change	15.31%	2.31%	-13.67%
Goodwill	$5.577M	$5.577M	$6.463M
YoY Change	-13.71%	277.33%	337.28%
Intangibles	$22.38M	$22.83M	$23.94M
YoY Change	-6.49%	258.71%	238.89%
Long-Term Investments		$57.20M
YoY Change
Other Assets	$0.00	$19.50M	$17.10M
YoY Change	-100.0%	96.97%	83.87%
Total Long-Term Assets	$135.6M	$185.7M	$121.8M
YoY Change	11.31%	92.32%	12.2%
TOTAL ASSETS
Total Short-Term Assets	$569.1M	$503.0M	$505.0M
Total Long-Term Assets	$135.6M	$185.7M	$121.8M
Total Assets	$704.7M	$688.7M	$626.8M
YoY Change	12.42%	12.86%	15.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.64M	$12.56M	$13.67M
YoY Change	7.1%	-14.78%	20.14%
Accrued Expenses	$25.90M	$19.96M	$28.95M
YoY Change	-10.54%	-11.17%	66.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.54M	$32.52M	$42.62M
YoY Change	-4.88%	-12.6%	48.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.600M	$2.700M	$3.000M
YoY Change	-13.33%	-3.57%	11.11%
Total Long-Term Liabilities	$0.00	$2.700M	$3.000M
YoY Change	-100.0%	-3.57%	11.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.54M	$32.52M	$42.62M
Total Long-Term Liabilities	$0.00	$2.700M	$3.000M
Total Liabilities	$40.54M	$40.20M	$47.00M
YoY Change	-13.75%	-6.73%	42.86%
SHAREHOLDERS EQUITY
Retained Earnings	$517.0M	$507.5M	$453.9M
YoY Change	13.9%	13.16%	11.0%
Common Stock	$164.5M	$159.2M	$146.7M
YoY Change	12.08%	17.08%	34.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$14.00K		$0.00
YoY Change
Treasury Stock Shares	93.00 shares	0.000 shares	0.000 shares
Shareholders Equity	$660.2M	$648.5M	$579.9M
YoY Change
Total Liabilities & Shareholders Equity	$704.7M	$688.7M	$626.8M
YoY Change	12.42%	12.86%	15.84%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	$9.512M	$18.81M	$5.463M
YoY Change	74.12%	15.62%	-25.9%
Depreciation, Depletion And Amortization	$4.700M	$4.000M	$4.800M
YoY Change	-2.08%	-6.98%	0.0%
Cash From Operating Activities	$21.20M	$26.90M	$6.300M
YoY Change	236.51%	38.66%	-48.78%
INVESTING ACTIVITIES
Capital Expenditures	-$8.700M	-$6.300M	-$5.400M
YoY Change	61.11%	103.23%	170.0%
Acquisitions
YoY Change
Other Investing Activities	$109.5M	-$79.80M	-$31.00M
YoY Change	-453.23%	-6750.0%	-684.91%
Cash From Investing Activities	$100.9M	-$86.00M	-$36.40M
YoY Change	-377.2%	4426.32%	-1170.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.500M	8.900M	13.40M
YoY Change	-88.81%	43.55%	24.07%
NET CHANGE
Cash From Operating Activities	21.20M	26.90M	6.300M
Cash From Investing Activities	100.9M	-86.00M	-36.40M
Cash From Financing Activities	1.500M	8.900M	13.40M
Net Change In Cash	123.6M	-50.20M	-16.70M
YoY Change	-840.12%	-311.81%	-163.02%
FREE CASH FLOW
Cash From Operating Activities	$21.20M	$26.90M	$6.300M
Capital Expenditures	-$8.700M	-$6.300M	-$5.400M
Free Cash Flow	$29.90M	$33.20M	$11.70M
YoY Change	155.56%	47.56%	-18.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000883984
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16330311	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	ICU MEDICAL INC/DE
	icui	Bargainpurchasegainnoncashaddback Bargainpurchasegainnoncashaddback	0	USD
	icui	Bargainpurchasegainnoncashaddback Bargainpurchasegainnoncashaddback	1456000	USD
	icui	Debt Securities Maturity Date Range High DebtSecuritiesMaturityDateRangeHigh	2042
	icui	Debt Securities Maturity Date Range Low DebtSecuritiesMaturityDateRangeLow	2016
CY2016Q3	icui	Dilutivesecuritiesadjustmentfrom Asu201609 DilutivesecuritiesadjustmentfromASU201609	413000	shares
	icui	Dilutivesecuritiesadjustmentfrom Asu201609 DilutivesecuritiesadjustmentfromASU201609	375000	shares
	icui	Grosslegalsettlementaward Grosslegalsettlementaward	8800000	USD
CY2016Q3	icui	Incometaxexcesstaxbenefitadjustment Asu201609 Adoption IncometaxexcesstaxbenefitadjustmentASU201609Adoption	3600000	USD
	icui	Incometaxexcesstaxbenefitadjustment Asu201609 Adoption IncometaxexcesstaxbenefitadjustmentASU201609Adoption	6600000	USD
	icui	Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes	1017000	USD
	icui	Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes	2691000	USD
CY2015Q3	icui	Legalawardnetoflegalexpenses Legalawardnetoflegalexpenses	5300000	USD
CY2015Q3	icui	Legalsettlementaccrual Legalsettlementaccrual	7100000	USD
	icui	Legalsettlementcharge Legalsettlementcharge	6500000	USD
CY2015Q3	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	-5261000	USD
	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	1798000	USD
	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	1800000	USD
CY2016Q3	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	0	USD
	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	0	USD
CY2015Q3	icui	Net Book Valueof Building NetBookValueofBuilding	2500000	USD
	icui	Operating Financingcashflowimpactof Asu201609 OperatingFinancingcashflowimpactofASU201609	6200000	USD
	icui	Operating Financingcashflowimpactof Asu201609 OperatingFinancingcashflowimpactofASU201609	6600000	USD
	icui	Paymentsfor Repurchaseof Equityincludingcommissions PaymentsforRepurchaseofEquityincludingcommissions	15400000	USD
	icui	Provision For Warranty And Returns ProvisionForWarrantyAndReturns	38000	USD
	icui	Provision For Warranty And Returns ProvisionForWarrantyAndReturns	-22000	USD
CY2015Q3	icui	Restructuringandstrategictransaction Restructuringandstrategictransaction	3411000	USD
	icui	Restructuringandstrategictransaction Restructuringandstrategictransaction	3411000	USD
CY2016Q3	icui	Restructuringandstrategictransaction Restructuringandstrategictransaction	2806000	USD
	icui	Restructuringandstrategictransaction Restructuringandstrategictransaction	4339000	USD
CY2015Q3	icui	Sellingpriceofbuilding Sellingpriceofbuilding	3600000	USD
CY2016Q3	icui	Strategictransactionexpenses Strategictransactionexpenses	2400000	USD
	icui	Strategictransactionexpenses Strategictransactionexpenses	3500000	USD
CY2016Q3	icui	Total Restructuring Charges TotalRestructuringCharges	400000	USD
	icui	Total Restructuring Charges TotalRestructuringCharges	800000	USD
CY2016Q3	icui	Treasury Stock Purchase Plan TreasuryStockPurchasePlan	40000000	USD
CY2016Q3	icui	Treasury Stock Purchase Plan Remaining Available TreasuryStockPurchasePlanRemainingAvailable	7200000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	57847000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13670000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	12555000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53638000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28948000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19961000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148728000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	156268000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20758000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18226000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	145125000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	157603000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1101000	USD
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1121000	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44000	shares
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2015Q4	us-gaap	Assets Assets	626825000	USD
CY2016Q3	us-gaap	Assets Assets	688699000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	505007000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	503049000	USD
CY2015Q4	us-gaap	Assets Held For Sale Long Lived Fair Value Disclosure AssetsHeldForSaleLongLivedFairValueDisclosure	4134000	USD
CY2016Q3	us-gaap	Assets Held For Sale Long Lived Fair Value Disclosure AssetsHeldForSaleLongLivedFairValueDisclosure	4249000	USD
CY2015Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4134000	USD
CY2016Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4249000	USD
CY2016Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	41233000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	106637000	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	41233000	USD
CY2016Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	49475000	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	57162000	USD
CY2015Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
CY2016Q2	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	1100000	USD
CY2016Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	346000	USD
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	1456000	USD
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	2600000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1106000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	595000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	275812000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	355368000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	336164000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	322963000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	79556000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-13201000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	377397000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	372438000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15595000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16307000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15595000	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16307000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	1608000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	1631000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	16770000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	31803000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	19506000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	56104000	USD
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	6003000	USD
CY2016Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	13688000	USD
CY2015Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2016Q3	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	39751000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	118741000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	45835000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	133046000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	17099000	USD
CY2016Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	19491000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1372000	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	5022000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13266000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14351000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.50
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.32
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.41
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.13
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-5848000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1664000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.31
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3638000	USD
CY2016Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3499000	USD
CY2015Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1086000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1100000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1086000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1102000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-40000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	6463000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	5577000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	46265000	USD
	us-gaap	Gross Profit GrossProfit	132540000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	51273000	USD
	us-gaap	Gross Profit GrossProfit	150638000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	24998000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	57058000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	23026000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	71075000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8732000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17536000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4220000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17503000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3246000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1587000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11390000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4736000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6915000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7314000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4867000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6635000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8824000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2228000	USD
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	681000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	619000	shares
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1086000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	987000	shares
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23936000	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22832000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14669000	USD
CY2016Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	17179000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	43632000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	50953000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	24681000	USD
CY2016Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	28940000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4282000	USD
CY2016Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	4834000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1451000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1026000	USD
	us-gaap	Legal Fees LegalFees	700000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	626825000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	688699000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42618000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32516000	USD
CY2015Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1476000	USD
CY2016Q3	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1197000	USD
CY2015Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1488000	USD
CY2016Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1488000	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	96909000	USD
CY2016Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	94446000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11613000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1036000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25161000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-84608000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48630000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	68707000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9305000	USD
	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	19717	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	174885	shares
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	225000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	996000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	449000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	21497000	USD
	us-gaap	Operating Expenses OperatingExpenses	76478000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	28818000	USD
	us-gaap	Operating Expenses OperatingExpenses	81468000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	24768000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	56062000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	22455000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	69170000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	504000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7719000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	700000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2532000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	345000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-1867000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-19000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	394000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	69000	USD
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	200000	USD
CY2015Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	125000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	405000	USD
CY2016Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	10000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	25000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1523000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	17155000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	5340000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1800000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2584000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	778000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	861000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	40217000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	111575000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7729000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15018000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7631000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6569000	USD
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	14366000	USD
CY2016Q3	us-gaap	Prepaid Taxes PrepaidTaxes	15202000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	70293000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	45429000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3592000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10974000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15830000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2162000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2361000	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	16266000	USD
	us-gaap	Profit Loss ProfitLoss	39522000	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	18806000	USD
	us-gaap	Profit Loss ProfitLoss	53572000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	223048000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	236856000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74320000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80588000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	53000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4227000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11657000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3650000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10301000	USD
	us-gaap	Restructuring Charges RestructuringCharges	621000	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	6539000	USD
CY2016Q3	us-gaap	Restructuring Reserve RestructuringReserve	1944000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-22000	USD
	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	146000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	453896000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	507468000	USD
CY2015Q3	us-gaap	Revenues Revenues	86016000	USD
	us-gaap	Revenues Revenues	251281000	USD
CY2016Q3	us-gaap	Revenues Revenues	97108000	USD
	us-gaap	Revenues Revenues	283684000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	85891000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	250876000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	97098000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	283659000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20206000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60698000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22362000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	66828000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11464000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	579871000	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	648476000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16575000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16409000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17286000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17100000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15894000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15790000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16200000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16113000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued No. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current generally accepted accounting principles prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until after the asset has been sold to an outside party. The amendments in ASU 2016-16 eliminates this prohibition, accordingly an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Amendments in this update are effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted in the first interim period of an annual reporting period. The amendments should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. </font><font style="font-family:inherit;font-size:10pt;">We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued No. ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">provides specific guidance on eight cash flow issues where current guidance is unclear or does not include any specifics on classification. The eight specific cash flow issues are: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with zero coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies, including bank-owned policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. The amendments in ASU 2016-15 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. If adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Amendments should be applied using a retrospective transition method to each period presented. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued No. ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December 15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued No. ASU 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued No. ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">        </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued No. ASU No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement of inventory from lower of cost or market to lower of cost and net realizable value. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. We do not anticipate a material impact on our consolidated financial statements from the adoption of this ASU.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU 2014-09.  On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. Subsequent to the issuance of this ASU, the FASB issued three amendments: ASU No. 2016-08 which clarifies principal versus agent considerations; ASU 2016-10 which clarifies guidance related to identifying performance obligations and licensing implementation; and ASU 2016-12 which provides narrow-scope improvements and practical expedients. All of the amendments have the same effective dates mentioned above. We do not anticipate a material impact on our consolidated financial statements from adoption of any of the above ASUs. We expect to adopt the full retrospective transition method when adopting this ASU.</font></div></div>

Files In Submission

Name	View Source	Status
0000883984-16-000084-index-headers.html	Edgar Link	pending
0000883984-16-000084-index.html	Edgar Link	pending
0000883984-16-000084.txt	Edgar Link	pending
0000883984-16-000084-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
icui-20160930.xml	Edgar Link	completed
icui-20160930.xsd	Edgar Link	pending
icui-20160930_cal.xml	Edgar Link	unprocessable
icui-20160930_def.xml	Edgar Link	unprocessable
icui-20160930_lab.xml	Edgar Link	unprocessable
icui-20160930_pre.xml	Edgar Link	unprocessable
icui-ex311_20160930x10q.htm	Edgar Link	pending
icui-ex312_x20160930x10q.htm	Edgar Link	pending
icui-ex321_x20160930x10q.htm	Edgar Link	pending
icui0930201610-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICUI
ICU Medical Inc Stock $icui

2016 Q4 Form 10-Q Financial Statement

#000088398416000084 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICUI ICU Medical Inc Stock $icui

2016 Q4 Form 10-Q Financial Statement

#000088398416000084 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICUI
ICU Medical Inc Stock $icui